Moneycontrol
HomeNewsBusinessEarningsCipla: Sailing well on the US pharma business front
Trending Topics
SBI Q1 Results
Manappuram Finance Q1 Results
Tata Motors Q1 results
Titan Q1 Preview
SBI Q1 Preview

Cipla: Sailing well on the US pharma business front

Anubhav Sahu   •

The company’s chronic portfolio continues to gain strength and the US base business has moved to a new orbit. This is supportive for medium-term earnings growth, which makes us constructive on the business.

Cipla posted an impressive set of numbers in Q1FY24, which turned out to be above expectations.

To read the full story,

Subscribe to Moneycontrol PRO
  • Ad-free Experience
  • Access Exclusive Stories
  • Weekly Investment Ideas
  • Daily Technical Calls

Are you a PRO subscriber? Sign In

What Do You Get

  • Ad free Experience

    Seamless navigation, faster responses.

  • Expert Perspective

    Explore 230+ exclusive editorials every month

  • +

    Uncover Insights from World-Renowned Experts and Journalists

  • Actionable Insights

    40+ weekly investment ideas + 3 to 4 daily technical calls

  • Virtual Events

    Exclusive Live Webinars for Expert Trading & Investment Strategies!

  • Newsletters

    Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More